Briacell Therapeutics CorpTSX:BCTView on NASDAQ
- LAST PRICE2.9300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.9400/ 5
- Ask / Lots3.5000/ 8
- Open / Previous Close0.0000 / 2.9300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCT |
|---|---|---|
| 10:33 ET | 100 | 3.01 |
| 10:35 ET | 800 | 2.99 |
| 10:44 ET | 300 | 2.91 |
| 11:02 ET | 100 | 2.95 |
| 02:31 ET | 200 | 3.01 |
| 03:25 ET | 400 | 2.93 |
Apr 24, 2024
BriaCell Announces Oral and Poster Presentations at ASCO 2024, from 8:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 10, 2024
Apr 9, 2024
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Briacell Therapeutics Corp | 46.9M | -2.6x | --- |
Nurexone Biologic Inc | 42.8M | -5.8x | --- |
KDA Group Inc | 70.2M | 199.0x | --- |
Defence Therapeutics Inc | 56.8M | -4.0x | --- |
ZYUS Life Sciences Corp | 74.4M | -3.6x | --- |
Satellos Bioscience Inc | 54.2M | -3.2x | --- |
Company Information
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.
Contact Information
- Headquarters
- 3rd Floor Bellevue Centre,, 235-15th StrWEST VANCOUVER, BC, Canada V7T 2X1
- Phone
- 604-921-1810
- Fax
- 604-921-1898
Executives
- Non-Executive Independent Chairman of the Board
- Jamieson Bondarenko
- President, Chief Executive Officer, Director
- William Williams
- Chief Financial Officer, Corporate Secretary
- Gadi Levin
- Chief Scientific Officer
- Miguel Lopez-Lago
- Chief Medical Officer
- Giuseppe Del Priore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.0M |
Briacell Therapeutics Corp does not pay a dividend. | |
Beta | 1.78 |
EPS | $-1.11 |
Book Value | $-0.32 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
